Diagnóstico y manejo | 18 MAY 09

Revisión: Cefaleas

Una de las principales razones de consulta neurológica. Es importante establecer un adecuado diagnóstico y tratamiento.
Autor/a: Mayela Rodríguez, Steve Vargas, Juan Manuel Calleja y Fernando Zermeño; INNN "Manuel Velasco Suárez" Fuente: Revista Dolor Clínica y Terapia Vol. VI/ Núm.2/ 2009
INDICE:  1. Desarrollo | 2. Referencias bibliográficas
Referencias bibliográficas

1. Leo AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7(6):359-390.

2. Grafstein B. Mechanism of spreading cortical depression. J Neurophysiol 1956;19(2):154-171.

3. Larrosa B, Pastor J, López-Aguado L, Herreras O. A role for glutamate and glia in the fast network oscillations preceding spreading depression. Neuroscience 2006;141(2):1057-1068.

4. Goldstein J, Ryan R, Jiang K, et al. Rizatriptan protocol 046 study group. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache 1998;38:737-747.

5. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668- 1675.

6. Loj J, Solomon GD. Migraine prophylaxis: who, why, and how. Cleve Clin J Med 2006 sep;73(9):793-4, 797, 800-801.

7. Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the spectrum study. Headache 2000;40:792-797.

8. Sheftell F, O’Quinn S, Watson C, Pait D, Winter P. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000;40:103-110.

9. Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience [published correction appears in Cephalalgia. 2001;21:164-165]. Cephalalgia 2000;20:687-695.

10. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004;(2):CD003225.

11. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36:695-699.

12. Peroutka SJ. 5-Hidroxytriptamine receptor subtypes and the pharmacology of migraine. Neurology 1993 (suppl 3): S34-S38.

13. Whewell J. Methysergide in prophylaxis of migraine: a clinical trial in general practice. Br Med J 1966 aug 13;2(5510):394-395.

14. Curran A, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry 1964 october; 27(5):463-469.

15. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril). BMJ 2001;322:19-22.

16. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003;289:65-69.

17. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K. MD for the Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-1659.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022